Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000174616 | SCV000225939 | uncertain significance | not provided | 2014-12-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000765501 | SCV000896802 | uncertain significance | Myopathy, centronuclear, 2 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000174616 | SCV001999549 | uncertain significance | not provided | 2019-12-03 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); The majority of missense variants in this gene are considered pathogenic (Stenson et al., 2014); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000765501 | SCV003486912 | uncertain significance | Myopathy, centronuclear, 2 | 2024-11-05 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 381 of the BIN1 protein (p.Pro381Leu). This variant is present in population databases (rs794727107, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with BIN1-related conditions. ClinVar contains an entry for this variant (Variation ID: 194281). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV000174616 | SCV004224946 | uncertain significance | not provided | 2022-12-06 | criteria provided, single submitter | clinical testing | BP4 |
Ambry Genetics | RCV004020069 | SCV004911926 | uncertain significance | Inborn genetic diseases | 2024-01-09 | criteria provided, single submitter | clinical testing | The c.1142C>T (p.P381L) alteration is located in exon 13 (coding exon 13) of the BIN1 gene. This alteration results from a C to T substitution at nucleotide position 1142, causing the proline (P) at amino acid position 381 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |